Research progress of PARP inhibitors therapy for endometrial cancer

doi:10.12092/j.issn.1009-2501.2026.04.013

Abstract

Abstract:

Endometrial cancer (EC) is the second most common gynecological malignancy worldwide. The standard treatment for endometrial cancer primarily involves surgical intervention, supplemented by radiotherapy, chemotherapy, and hormonal therapies as part of a comprehensive treatment approach. In the early stages of endometrial cancer, most patients exhibit no significant positive signs, and they often present at advanced stages, leading to poor prognoses with standard treatment regimens for advanced or recurrent endometrial cancer. Therefore, there is an urgent clinical need for new therapeutic methods to improve the prognosis of patients with endometrial cancer. With advancements in molecular biology techniques, molecular targeted therapy has become a focal point of research. PARP inhibitors, as emerging targeted therapeutic agents, inhibit the progression of endometrial cancer through a synthetic lethality effect. This article will review the potential of PARP inhibitors in the treatment of endometrial cancer, with the hope of providing new strategies for clinical management of the disease.

Key words: PARP inhibitors, endometrial cancer, therapeutic mechanism, combination use, prognosis

CLC Number:

Shouyan HE, Minjun LIU, Cong WAN, Buzhen TAN. Research progress of PARP inhibitors therapy for endometrial cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(4): 536-542.

Figures/Tables 2

References 40

1	Azadehrah M, Vosoogh S, Azadehrah M. The roles and therapeutic applications of cytokines in endometrial cancer[J]. J Reprod Immunol, 2022, 152, 103652. doi: 10.1016/j.jri.2022.103652
2	Tang YH, Lin CY, Lai CH. Development of new cancer treatment by identifying and focusing the genetic mutations or altered expression in gynecologic cancers[J]. Genes (Basel), 2021, 12 (10): 1586.
3	Merkuryev AV, Egorov VV. Role of PARP-1 structural and functional features in PARP-1 inhibitors development[J]. Bioorg Chem, 2025, 156, 108188. doi: 10.1016/j.bioorg.2025.108188
4	Elkatary RG, El Beltagy HM, Abdo VB, et al. Poly (ADP-ribose) polymerase pathway inhibitor (Olaparib) upregulates SERCA2a expression and attenuates doxorubicin-induced cardiomyopathy in mice[J]. Environ Toxicol Pharmacol, 2023, 103, 104261. doi: 10.1016/j.etap.2023.104261
5	于蕾, 杨清, 毕芳芳. PARP-1在子宫内膜样腺癌中的表达[J]. 现代肿瘤医学, 2013, 21 (4): 849- 52. doi: 10.3969/j.issn.1672-4992.2013.04.59
6	Kacperczyk-Bartnik J, Bartnik P, Goławski K, et al. Plasma and peritoneal poly (ADP-Ribose) polymerase levels in patients with endometriosis[J]. Biomedicines, 2022, 10 (10): 2451. doi: 10.3390/biomedicines10102451
7	Kaur SD, Chellappan DK, Aljabali AA, et al. Recent advances in cancer therapy using PARP inhibitors[J]. Med Oncol, 2022, 39 (12): 241. doi: 10.1007/s12032-022-01840-7
8	Pei X, Mladenov E, Soni A, et al. PTEN loss enhances error-prone DSB processing and tumor cell radiosensitivity by suppressing RAD51 expression and homologous recombination[J]. Int J Mol Sci, 2022, 23 (21): 12876. doi: 10.3390/ijms232112876
9	Piha-Paul SA, Tseng C, Leung CH, et al. Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations[J]. NPJ Precis Oncol, 2024, 8 (1): 166. doi: 10.1038/s41698-024-00634-6
10	Janzen DM, Paik DY, Rosales MA, et al. Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo[J]. Mol Cancer Ther, 2013, 12 (12): 2917- 2928. doi: 10.1158/1535-7163.MCT-13-0572
11	Madariaga A, Garg S, Tchrakian N, et al. Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma[J]. Nat Commun, 2023, 14 (1): 1452. doi: 10.1038/s41467-023-37084-w
12	Martorana F, Da Silva LA, Sessa C, et al. Everything comes with a price: the toxicity profile of DNA-damage response targeting agents[J]. Cancers (Basel), 2022, 14 (4): 1014.
13	Hage Chehade C, Gebrael G, Sayegh N, et al. A pan-tumor review of the role of poly (adenosine diphosphate ribose) polymerase inhibitors[J]. CA Cancer J Clin, 2025, 75 (2): 141- 167.
14	Gong X, Liu C, Tang H, et al. Application and research progress of synthetic lethality in the development of anticancer therapeutic drugs[J]. Front Oncol, 2024, 14, 1460412. doi: 10.3389/fonc.2024.1460412
15	郑小卫, 沈源明, 张英丽, 等. 多腺苷二磷酸核糖聚合酶抑制剂不良反应管理指导意见[J]. 浙江大学学报(医学版), 2022, 51 (6): 765- 774. doi: 10.3724/zdxbyxb-2022-0284
16	Zhang X, Huang P, Wang L, et al. Inhibition of BAD-Ser99 phosphorylation synergizes with PARP inhibition to ablate PTEN-deficient endometrial carcinoma[J]. Cell Death Dis, 2022, 13 (6): 558. doi: 10.1038/s41419-022-04982-8
17	Wang R, Liu Y, Liu M, et al. Combating tumor PARP inhibitor resistance: Combination treatments, nanotechnology, and other potential strategies[J]. Int J Pharm, 2025, 669, 125028. doi: 10.1016/j.ijpharm.2024.125028
18	Wang J, Li H, He G, et al. Discovery of novel dual poly (ADP-ribose) polymerase and phosphoinositide 3-kinase inhibitors as a promising strategy for cancer therapy[J]. J Med Chem, 2020, 63 (1): 122- 139. doi: 10.1021/acs.jmedchem.9b00622
19	Paraghamian SE, Qiu J, Hawkins GM, et al. A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer[J]. Cancer Biol Ther, 2023, 24 (1): 2202104. doi: 10.1080/15384047.2023.2202104
20	Bhamidipati D, Haro-Silerio JI, Yap TA, et al. PARP inhibitors: enhancing efficacy through rational combinations[J]. Br J Cancer, 2023, 129 (6): 904- 916. doi: 10.1038/s41416-023-02326-7
21	Zhang A, Zhang L, Xie X, et al. Inhibition of ATM with KU-55933 sensitizes endometrial cancer cell lines to olaparib[J]. Onco Targets Ther, 2023, 16, 1061- 1071. doi: 10.2147/OTT.S426923
22	Zhu Y, Liu K, Zhu H. Immune checkpoint inhibitor combinations for patients with advanced endometrial cancer: a network meta-analysis and cost-utility analysis[J]. Int J Gynecol Cancer, 2024, 34 (3): 319- 328. doi: 10.1016/j.ijgc.2025.101680
23	Yi M, Niu M, Xu L, et al. Regulation of PD-L1 expression in the tumor microenvironment[J]. J Hematol Oncol, 2021, 14 (1): 10. doi: 10.1186/s13045-020-01027-5
24	Silk T, Hacker KE, Growdon W, et al. The advent of immune checkpoint inhibition for the treatment of patients with primary advanced or recurrent dMMR/MSI high endometrial cancer in 2025[J]. Curr Opin Obstet Gynecol, 2025, 37 (1): 22- 29. doi: 10.1097/GCO.0000000000001004
25	Konstantinopoulos PA, Gockley AA, Xiong N, et al. Evaluation of treatment with talazoparib and avelumab in patients with recurrent mismatch repair proficient endometrial cancer[J]. JAMA Oncol, 2022, 8 (9): 1317- 1322. doi: 10.1001/jamaoncol.2022.2181
26	Post C CB, Westermann AM, Boere IA, et al. Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)[J]. Gynecol Oncol, 2022, 165 (2): 223- 229. doi: 10.1016/j.ygyno.2022.02.025
27	van de Ven AL, Tangutoori S, Baldwin P, et al. Nanoformulation of olaparib amplifies PARP inhibition and sensitizes PTEN/TP53-deficient prostate cancer to radiation[J]. Mol Cancer Ther, 2017, 16 (7): 1279- 1289. doi: 10.1158/1535-7163.MCT-16-0740
28	Wang J, Xing W, Lin Y, et al. Blocking PARP activity with the inhibitor veliparib enhances radiotherapy sensitivity in endometrial carcinoma[J]. J Clin Lab Anal, 2022, 36 (5): e24435. doi: 10.1002/jcla.24435
29	Lesueur P, Chevalier F, Austry JB, et al. Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies[J]. Oncotarget, 2017, 8 (40): 69105- 69124. doi: 10.18632/oncotarget.19079
30	Duan M, Leng S, Mao P. Cisplatin in the era of PARP inhibitors and immunotherapy[J]. Pharmacol Ther, 2024, 258, 108642. doi: 10.1016/j.pharmthera.2024.108642
31	Erratum: Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: The phase III DUO-E trial [J]. J Clin Oncol, 2024, 42(27): 3262.
32	Murakami K, Takamura S, Kakimi K, et al. Tumor immunology and immunotherapy for endometrial cancer[J]. Expert Opin Investig Drugs, 2025, 34 (1/2): 37- 48.
33	Di Dio C, Bogani G, Di Donato V, et al. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma[J]. Gynecol Oncol, 2023, 169, 27- 33. doi: 10.1016/j.ygyno.2022.11.031
34	Piffoux M, Leary A, Follana P, et al. Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial[J]. Nat Commun, 2025, 16 (1): 1821. doi: 10.1038/s41467-025-56914-7
35	Joly F, Leary A, Ray-Coquard I, et al. Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial[J]. Nat Commun, 2025, 16 (1): 7950. doi: 10.1038/s41467-025-62678-x
36	王梦琦, 杨敬敬, 王文桃. 多腺苷二磷酸核糖聚合酶抑制剂联合化疗在晚期子宫内膜癌治疗中的应用价值[J]. 癌症进展, 2021, 19 (13): 1371- 1373+85. doi: 10.11877/j.issn.1672-1535.2021.19.13.20
37	Kuznicki ML, Mallen A, Ha K, et al. Prognostic features of endometrial cancer metastasis to the central nervous system[J]. PLoS One, 2022, 17 (8): e0268794. doi: 10.1371/journal.pone.0268794
38	Wang Q, Zhang F, Gao H, et al. Successful treatment of a patient with brain metastases from endometrial cancer using Niraparib: a case report[J]. Ann Palliat Med, 2021, 10 (1): 818- 827. doi: 10.21037/apm-21-113
39	Forster MD, Dedes KJ, Sandhu S, et al. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer[J]. Nat Rev Clin Oncol, 2011, 8 (5): 302- 306. doi: 10.1038/nrclinonc.2011.42
40	Bai YR, Yang WG, Jia R, et al. The recent advance and prospect of poly(ADP-ribose) polymerase inhibitors for the treatment of cancer[J]. Med Res Rev, 2025, 45 (1): 214- 273. doi: 10.1002/med.22069

Drug	Company	Progress	Time of first approval	Time of approval in China	Indication
Olaparib	AstraZeneca/ MSD	marketed	2014-12	2018-08	1.Maintenance therapy for platinum-sensitive recurrent ovarian cancer; 2.first-line maintenance therapy for advanced ovarian cancer with BRCA1/2mutation; 3.BRCAmutation and previous treatment failure of denervation-resistant prostate; 4.Combined with bevacizumab for first-line maintenance treatment of HRD-positive ovarian cancer.
Rukapani	Clovis	marketed	2016-12	/	/
Niraparib	GSK/Zai Lab	marketed	2017-03	2019-12	1.Maintenance therapy for platinum-sensitive recurrent ovarian cancer; 2.First-line maintenance therapy for platinum-sensitive recurrent ovarian cancer.
Taprazopanib	Pfizer	marketed	2018-10		/
Fluzoparib	Heng Rui/ Hansoh	marketed	2020-12	2020-12	1.Third-line treatment of platinum-sensitive recurrent ovarian cancer with germline BRCA mutations; 2.Maintenance therapy for platinum-sensitive recurrent ovarian cancer.
Pamiparib	BeOne Medicines Ltd	marketed	2021-04	2021-04	Third-line treatment of platinum-sensitive recurrent ovarian cancer with germline BRCA mutations.
Senapari	Impact	NDA	/	/	First-line maintenance therapy for advanced ovarian cancer.

Drug	Company	Progress	Time of first approval	Time of approval in China	Indication
Olaparib	AstraZeneca/ MSD	marketed	2014-12	2018-08	1.Maintenance therapy for platinum-sensitive recurrent ovarian cancer; 2.first-line maintenance therapy for advanced ovarian cancer with BRCA1/2mutation; 3.BRCAmutation and previous treatment failure of denervation-resistant prostate; 4.Combined with bevacizumab for first-line maintenance treatment of HRD-positive ovarian cancer.
Rukapani	Clovis	marketed	2016-12	/	/
Niraparib	GSK/Zai Lab	marketed	2017-03	2019-12	1.Maintenance therapy for platinum-sensitive recurrent ovarian cancer; 2.First-line maintenance therapy for platinum-sensitive recurrent ovarian cancer.
Taprazopanib	Pfizer	marketed	2018-10		/
Fluzoparib	Heng Rui/ Hansoh	marketed	2020-12	2020-12	1.Third-line treatment of platinum-sensitive recurrent ovarian cancer with germline BRCA mutations; 2.Maintenance therapy for platinum-sensitive recurrent ovarian cancer.
Pamiparib	BeOne Medicines Ltd	marketed	2021-04	2021-04	Third-line treatment of platinum-sensitive recurrent ovarian cancer with germline BRCA mutations.
Senapari	Impact	NDA	/	/	First-line maintenance therapy for advanced ovarian cancer.

[1]	Jiawang YU, Guomei LI, Changbao HUANG, Ning TANG, Weihua LU, Feng ZHOU. Study on a nomogram model for predicting the prognosis of patients with acute organophosphorus pesticide poisoning in Southern Anhui [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(4): 460-466.
[2]	Qianmin ZENG, Jiejun ZHAO, Yaming XI. Research status of immunoparesis in multiple myeloma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(4): 561-567.
[3]	SONG Cong, GAO Jinglin, BAN Feng, MENG Meng, WANG Mingxia. Research progress of PARP inhibitors in the treatment of brain glioma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(9): 1281-1289.
[4]	DING Qin, YANG Ruwei, ZHANG Shengnan, YANG Guoping, PEI Qi. Time-to-event analysis in evaluating the efficacy of drugs against multidrug-resistant gram-negative bacterial infections [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(7): 998-1008.
[5]	XU Tingting, WANG Wanjie, BAO Jing, XIA Ruixiang. The relationship between NLRC4-mediated inflammasome pathway and multiple myeloma and its therapeutic prospect [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(4): 501-508.
[6]	ZHANG Liyi, GUO Zifen. Research advance in progesterone therapy for endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(2): 230-235.
[7]	WANG Mengjiao, GAO Chao, WANG Tao, ZHANG Qian, WEN Juan, LV Dongmei, HU Lili. CDA C435T gene polymorphism significantly extends the long-term efficacy of gemcitabine in advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(12): 1337-1343.
[8]	SHI Dawei, ZHENG Xiaoyong, JIN Xiaodan, ZHAO Xiaoman, CHEN Jie, DU Xingjun. Implication of XPC rs2228001 polymorphism on the prognosis of patients with colorectal cancer who were treated with capecitabine-based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 391-399.
[9]	HUANG Kaige, XU Qinhua, WANG Wei. Interaction effect and predictive efficacy of blood glucose and blood calcium on the prognosis of patients with acute severe pancreatitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1227-1234.
[10]	HUANG Hao, JIA Hong, WANG Xiaoshuang, ZHANG Lu, JIANG Hua. Effects of co-culture of dendritic cells loaded with MAGE-A3 antigen and cytokine-induced killer cells on tumor stem cells and malignant progression of endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 42-50.
[11]	HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle. Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
[12]	LIU Le, QI Wenbo, BAI Yuping, LIU Qian, YIN Zhenyu, LI Xiaomei, YU Yang, CHEN Hao. Influencing factors of PD-1/PD-L1 immune checkpoint inhibitor immunotherapy for gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 95-101.
[13]	ZHENG Ying, ZHANG Ling, YAO Li, WANG Qianhe, ZHU Kexiang. Research progress of PARP inhibitors in pancreatic cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 108-115.
[14]	TIAN Yali, FENG Lin, ZHAO Wan, GU Min, SHEN Hanjing, CHAI Xiaoyan. Correlation of BRCA1 gene polymorphism with chemosensitivity and prognosis of metastatic esophageal squamous cell carcinoma treated with cisplatin combined with capecitabine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1118-1126.
[15]	XU Honglei, XU Bingxin, ZU Qing, ZHAO Yan, GAO Pengfei, YU Yang. Effects of CYP2C19 gene polymorphism on the clinical prognosis of clopidogrel in elderly patients with acute cerebral infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1014-1020.